MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412346 | Name: Visnadine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Visnadine is a natural vasodilator. It was first isolated from bishop's weed, a plant indigenous to the Mediterranean region which has been used for centuries in Egypt as a spasmolytic.

Chemical Structure

Visnadine
Visnadine
CAS#477-32-7

Theoretical Analysis

MedKoo Cat#: 412346

Name: Visnadine

CAS#: 477-32-7

Chemical Formula: C21H24O7

Exact Mass: 388.1522

Molecular Weight: 388.42

Elemental Analysis: C, 64.94; H, 6.23; O, 28.83

Price and Availability

Related CAS #
No Data
Synonym
Visnadine; BRN0055264; BRN-0055264; BRN 0055264
IUPAC/Chemical Name
(9R,10R)-10-acetoxy-8,8-dimethyl-2-oxo-9,10-dihydro-2H,8H-pyrano[2,3-f]chromen-9-yl (R)-2-methylbutanoate
InChi Key
GVBNSPFBYXGREE-CXWAGAITSA-N
InChi Code
InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1
SMILES Code
CC[C@H](C(O[C@@H]1[C@@H](c2c3c(C=CC(O3)=O)ccc2OC1(C)C)OC(C)=O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 388.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Raju S, Murugan K, Nand M, Mathpal S, Chandra S, Ramakrishnan MA, Maiti P. Identification of novel fructose 1,6-bisphosphate aldolase inhibitors against tuberculosis: QSAR, molecular docking, and molecular dynamics simulation-based analysis of DrugBank compounds. J Biomol Struct Dyn. 2024 Dec 11:1-14. doi: 10.1080/07391102.2024.2436552. Epub ahead of print. PMID: 39661778. 2: Caira-Chuquineyra B, Fernandez-Guzmán D, Garayar-Peceros H, Benites-Zapata VA, Pérez-López FR, Blümel JE, Mezones-Holguín E. Efficacy and safety of visnadine in the treatment of symptoms of sexual dysfunction in heterosexual women: a systematic review of randomized clinical trials. Gynecol Endocrinol. 2024 Dec;40(1):2328619. doi: 10.1080/09513590.2024.2328619. Epub 2024 Mar 25. PMID: 38528806. 3: Çatıkkaş B, Karacan N. Molecular Docking and Dynamics Simulations of Ammi visnaga L. Constituents as Antimelanogenic, Anti-Inflammatory and Anticoagulant Agents. Chem Biodivers. 2023 Nov;20(11):e202301184. doi: 10.1002/cbdv.202301184. Epub 2023 Oct 18. PMID: 37850550. 4: Sparavigna A, Caputo A, Natoli A, Mandelli C. A randomized single-blind placebo-controlled study of a Visnadine Emulgel formulation on healthy postmenopausal women. Minerva Ginecol. 2019 Oct;71(5):353-358. doi: 10.23736/S0026-4784.19.04398-3. PMID: 31698889. 5: Caputo A, Sparavigna A, Natoli A, Mandelli C. An open trial of a Visnadine emulgel topical application in postmenopausal superficial dyspareunia: daily vs. on-demand use. Minerva Ginecol. 2020 Feb;72(1):59-60. doi: 10.23736/S0026-4784.19.04402-2. Epub 2019 Sep 20. PMID: 31560182. 6: Caputo A, Natoli A, Radice R, Zanardi G, Giacomelli L. Efficacy of an intimate oil solution containing visnadine in women self-reporting sexual symptoms. Minerva Ginecol. 2018 Aug;70(4):492-493. doi: 10.23736/S0026-4784.18.04209-0. PMID: 29952501. 7: Laganà AS, Vitale SG, Stojanovska L, Lambrinoudaki I, Apostolopoulos V, Chiofalo B, Rizzo L, Basile F. Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas. 2018 Mar;109:78-80. doi: 10.1016/j.maturitas.2017.12.015. Epub 2017 Dec 24. PMID: 29452786. 8: Bernorio R, Piloni S, Mori G, Prunas A, Bosoni D, Nappi RE. Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. J Endocrinol Invest. 2018 Jun;41(6):729-737. doi: 10.1007/s40618-017-0801-0. Epub 2017 Dec 11. PMID: 29230716. 9: Caruso S, Mauro D, Cariola M, Fava V, Rapisarda AMC, Cianci A. Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder. Gynecol Endocrinol. 2018 Feb;34(2):110-114. doi: 10.1080/09513590.2017.1354366. Epub 2017 Jul 27. PMID: 28749253. 10: Winderl B, Schwaiger S, Ganzera M. Fast and improved separation of major coumarins in Ammi visnaga (L.) Lam. by supercritical fluid chromatography. J Sep Sci. 2016 Oct;39(20):4042-4048. doi: 10.1002/jssc.201600734. Epub 2016 Sep 8. PMID: 27514847. 11: Bassino E, Antoniotti S, Gasparri F, Munaron L. Effects of flavonoid derivatives on human microvascular endothelial cells. Nat Prod Res. 2016 Dec;30(24):2831-2834. doi: 10.1080/14786419.2016.1154053. Epub 2016 Mar 2. PMID: 26936689. 12: Menghini L, Epifano F, Genovese S, Marcotullio MC, Sosa S, Tubaro A. Antiinflammatory activity of coumarins from Ligusticum lucidum Mill. subsp. cuneifolium (Guss.) Tammaro (Apiaceae). Phytother Res. 2010 Nov;24(11):1697-9. doi: 10.1002/ptr.3170. PMID: 21031631. 13: Zgórka G, Dragan T, Głowniak K, Basiura E. Determination of furanochromones and pyranocoumarins in drugs and Ammi visnaga fruits by combined solid-phase extraction-high-performance liquid chromatography and thin-layer chromatography- high-performance liquid chromatography. J Chromatogr A. 1998 Feb 27;797(1-2):305-9. doi: 10.1016/s0021-9673(97)01173-4. PMID: 9542122. 14: Durate J, Vallejo I, Pérez-Vizcaino F, Jiménez R, Zarzuelo A, Tamargo J. Effects of visnadine on rat isolated vascular smooth muscles. Planta Med. 1997 Jun;63(3):233-6. doi: 10.1055/s-2006-957660. PMID: 9225605. 15: Rauwald HW, Brehm O, Odenthal KP. The involvement of a Ca2+ channel blocking mode of action in the pharmacology of Ammi visnaga fruits. Planta Med. 1994 Apr;60(2):101-5. doi: 10.1055/s-2006-959426. PMID: 8202556. 16: Nosovskaia TD, Privalova EG, Zhukov GA, Prokopenko AP. Dynamika nahromadzhennia visnadynu v ami zubniĭ protiahom vehetatsiĭnoho periodu [Dynamics of visnadin accumulation in Ammi visnaga during the vegetative period]. Farm Zh. 1978 Jan-Feb;(1):81-3. Ukrainian. PMID: 415903. 17: Krivut BA, Perel'son ME. Spektrofotometricheskoe opredelenie digidrosamidina i visnadina [Spectrophotometric determination of dihydrosamidine and visnadin]. Farmatsiia. 1973 Jul-Aug;22(4):40-2. Russian. PMID: 4754247. 18: Eyraud H, Aurousseau M. Study of the action of visnadine on general and cardiac hemodynamics. Arzneimittelforschung. 1973 Feb;23(2):201-7. PMID: 4739830. 19: Ladygina EIa. Lokalizatsiia visnadina i digidrosamidina v podzemnykh organakh vzdutoplodnika sibirskogo Phleojodicarpus sibiricus (Steph.) K. Pol [Localization of visnadin and dihydrosamidine in underground organs of Phlojodicarpus sibiricus (Steph.) K. Pol]. Farmatsiia. 1970 Jul-Aug;19(4):30-6. Russian. PMID: 5488015. 20: Kiesewetter E. Koronartherapie mit Visnadin [Coronary treatment with visnadine]. Wien Med Wochenschr. 1969 May 3;119(18):346-7. German. PMID: 4979695.

View History

LX-201 cation

LX-201 cation